Skip to main content

Table 1 Correlation between the expressions of miR-17 and miR-92 families and the clinicopathological features of NSCLC patients

From: The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer

Clinicopathological factors

Expression level of 6 miRNAsa

χ2 value

P value

High (n = 20)

Low (n = 19)

Histological type

Adenocarcinoma

12

10

0.216

0.642

Squamous carcinoma

8

9

Gender

Male

14

15

0.407

0.523

Female

6

4

Age (years)

<60

9

7

0.265

0.607

≥60

11

12

Smoking

Nonsmoker

8

8

0.019

0.891

Smoker

12

11

TNM Clinical stage

IIIB

5

8

1.288

0.256

IV

15

11

Chemotherapy regimensb

DDP + TXT

9

6

0.745

0.689

DDP + GEM

6

7

DDP + NVB

5

6

Chemotherapy responsec

CR + PR

7

13

4.366

0.036*

SD + PD

13

6

  1. (* P < 0.05)
  2. aExpression level of 6 miRNAs (miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25) was used the sum of scores as categorical variables, where each miRNA was dichotomised and its categories represented by the score of 0 or 1 as follows: score 0 (low risk) = miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25 levels ≥ median; score 1(high risk) = converse of criteria for score 0
  3. bDDP cisplatin, TXT docetaxel, GEM gemcitabine, NVB vinorelbine
  4. cCR complete response, PR partial response, SD stable disease, PD progressive disease